UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035009
Receipt number R000039918
Scientific Title Evaluation of diagnostic test and curative effect for the superficial bladder cancer based oral 5-aminolevulinic acid (5-ALA) prior to transurethral resection (TUR)
Date of disclosure of the study information 2018/11/26
Last modified on 2018/11/26 19:18:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of diagnostic test and curative effect for the superficial bladder cancer based oral 5-aminolevulinic acid (5-ALA) prior to transurethral resection (TUR)

Acronym

The significance of oral 5-aminolevulinic acid (5-ALA) for superficial bladder cancer

Scientific Title

Evaluation of diagnostic test and curative effect for the superficial bladder cancer based oral 5-aminolevulinic acid (5-ALA) prior to transurethral resection (TUR)

Scientific Title:Acronym

The significance of oral 5-aminolevulinic acid (5-ALA) for superficial bladder cancer

Region

Japan


Condition

Condition

superficial bladder cancer

Classification by specialty

Urology Adult

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To perform comparative examination for the detection lesions by fluorescent light (FL) between cancerous lesion s and non cancerous lesions

Basic objectives2

Others

Basic objectives -Others

To confirm the recurrence rate of superficial bladder cancer using oral 5-ALA prior to TUR

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

We study to confirm the superficial bladder cancer by parts of bladder with oral 5-ALA(20mg/kg) prior to TUR

Key secondary outcomes

To evaluate the recurrence rate by parts of bladder with oral(20mg/kg) 5-ALA prior to TUR at 3, 6, 9 and 12 months later from TUR


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

superficial cancer

Key exclusion criteria

progressive cancer

Target sample size

500


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hironori Betsunoh

Organization

Dokkyo Medical University

Division name

Urology

Zip code


Address

880Kitakobayashi Mibu, Shimotsuga Tochigi 321-0293 JAPAN

TEL

0282872162

Email

hirobets@dokkyomed.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hironori Betsunoh

Organization

Dokkyo Medical University

Division name

Urology

Zip code


Address

880Kitakobayashi Mibu, Shimotsuga Tochigi 321-0293 JAPAN

TEL

0282872162

Homepage URL


Email

hirobets@dokkyomed.ac.jp


Sponsor or person

Institute

Dokkyo Medical University, Department of Urology

Institute

Department

Personal name



Funding Source

Organization

Dokkyo Medical University, Department of Urology

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

獨協医科大学


Other administrative information

Date of disclosure of the study information

2018 Year 11 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2018 Year 11 Month 25 Day

Date of IRB


Anticipated trial start date

2018 Year 11 Month 26 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

To confirm the detection lesion as cancer by fluorescent light. To follow the recurrence or not after TUR.


Management information

Registered date

2018 Year 11 Month 26 Day

Last modified on

2018 Year 11 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039918


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name